Anzeige
Mehr »
Login
Freitag, 18.10.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
5 Millionen Unzen und steigend: NexGold Mining's unerschlossene Goldstraße
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QB38 | ISIN: US8334451098 | Ticker-Symbol: 5Q5
Tradegate
17.10.24
21:42 Uhr
109,52 Euro
-0,40
-0,36 %
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
SNOWFLAKE INC Chart 1 Jahr
5-Tage-Chart
SNOWFLAKE INC 5-Tage-Chart
RealtimeGeldBriefZeit
109,48110,1617.10.
109,36110,4617.10.
ACCESSWIRE
814 Leser
Artikel bewerten:
(2)

Amdocs Management Limited: Amdocs Named Snowflake Telecom AI Data Cloud Services Partner of the Year 2024

The award recognizes Amdocs' innovative accomplishments and track record in driving AI Data Cloud adoption in the telecom industry

JERSEY CITY, NJ / ACCESSWIRE / June 6, 2024 / Amdocs (NASDAQ:DOX), a leading provider of software and services to communications and media companies, today announced at Snowflake's annual user conference, Snowflake Data Cloud Summit 2024, that it has been named the 2024 Telecom AI Data Cloud Services Partner of the Year award winner by Snowflake, the AI Data Cloud company.

Amdocs was recognized for its achievements as part of the Snowflake AI Data Cloud, demonstrating a strong track record in driving telecom data cloud adoption through its industry expertise, services and solutions delivered alongside Snowflake. Amdocs provides SaaS-based data analytics solutions tailored for telecom common use cases using Snowflake's platform capabilities.

The award marks a key milestone in the strategic collaboration between Amdocs and Snowflake, further strengthening their partnership to facilitate seamless integration of data analytics solutions for communication service providers (CSPs).

"We are thrilled to be recognized as 'Telecom AI Data Cloud Services Partner of the Year' by Snowflake, which highlights our expertise and commitment to delivering exceptional services that enable our customers to provide outstanding experiences to billions of people around the world," said Anthony Goonetilleke, Group President of Technology and Head of Strategy, Amdocs. "As the foundation of service provider, AI & generative AI strategies, data readiness and cloud adoption has never been more important, and our collaboration with Snowflake brings SaaS-based data intelligence capabilities directly into their environment to ensure that customers can quickly and effectively execute on those strategies."

"Amdocs' recognition as Snowflake's Telecom AI Data Cloud Services Partner of the Year is a testament to the value they deliver to the AI Data Cloud ecosystem, and our shared mission of empowering organizations to unlock their data for business value," said Tyler Prince, SVP of Worldwide Alliances & Channels, Snowflake. "We look forward to continuing to build our partnership with Amdocs and are focused on the next generation of innovation."

Supporting Resources

  • Keep up with Amdocs news by visiting the company's website
  • Follow us on X, Facebook, LinkedIn and YouTube

About Amdocs

Amdocs helps those who build the future to make it amazing. With our market-leading portfolio of software products and services, we unlock our customers' innovative potential, empowering them to provide next-generation communication and media experiences for both the individual end user and enterprise customers. Our approximately 29,000 employees around the globe are here to accelerate service providers' migration to the cloud, enable them to differentiate in the 5G era, and digitalize and automate their operations. Listed on the NASDAQ Global Select Market, Amdocs had revenue of $4.89 billion in fiscal 2023. For more information, visit www.amdocs.com

Amdocs' Forward-Looking Statement

This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' growth and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general macro-economic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other global or regional events such as the October 7, 2023 attacks in Israel and evolving conflict and the COVID-19 pandemic, as well as the current inflationary environment, and the effects of these conditions on the company's customers' businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the company's customers, Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the company's offerings and operations and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2023 filed on December 13, 2023 and our Form 6-K furnished for the first quarter of fiscal 2024 on February 20, 2024, and for the second quarter of fiscal 2024 on May 20, 2024.

Media Contacts

Swati Sharma
Amdocs Public Relations
E-mail: swati.sharma4@amdocs.com

SOURCE: Amdocs



View the original press release on accesswire.com

© 2024 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.